SS
CYTK icon

SBI Securities’s Cytokinetics CYTK Stock Holding History

SBI Securities’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$937 Sell
11
-105
-91% -$7.54K ﹤0.01% 2832
2026
Q1 		$7.65K Sell
116
-102
-47% -$6.48K ﹤0.01% 1849
2025
Q4 		$13.9K Buy
218
+115
+112% +$7.15K ﹤0.01% 1585
2025
Q3 		$5.66K Buy
103
+101
+5,050% +$4.16K ﹤0.01% 1987
2025
Q2 		$66 Sell
2
-60
-97% -$2.09K ﹤0.01% 3654
2025
Q1 		$2.49K Hold
62
– – ﹤0.01% 2198
2024
Q4 		$2.92K Buy
+62
New +$3.22K ﹤0.01% 2130

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SBI Securities's CYTK Position: Q2 2026 in Review

SBI Securities reduced its Cytokinetics (CYTK) stake by 91% in Q2 2026, selling an estimated $7.54K and leaving 11 shares worth $937. The position accounts for ﹤0.01% of the portfolio, ranked #2832.

SBI Securities first reported a position in CYTK in Q4 2024 and has held it in 7 quarters since. The position peaked at $13.9K in Q4 2025. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • SBI Securities held 11 shares of Cytokinetics worth $937 as of Q2 2026.
  • SBI Securities sold 105 Cytokinetics shares in Q2 2026, an estimated $7.54K.
  • Cytokinetics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #2832 holding.
  • SBI Securities first reported a position in Cytokinetics in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Cytokinetics position peaked at $13.9K in Q4 2025.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.